Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Sexually Transmitted Diseases

Free Subscription Articles published in Oral Oncol Retrieve available abstracts of 138 articles: HTML format

Single Articles

September 2026
1. NYIRJESY SC, de Groot ECM, Chang YS, Romo LV, et al
   Accuracy of radiographic nodal counts in HPV-positive oropharyngeal cancer and impact on treatment.
   Oral Oncol. 2026;182:108127.
   PubMed     Abstract available
   
   
   
2. JABLONSKA IA, Rutkowski TW, Kacorzyk U, Kentnowski M, et al
   Circulating tumor HPV DNA reappearance as an early indicator of recurrence after radiotherapy-based treatment for HPV-associated oropharyngeal cancer: analysis of more than 2000 assessments in 232 patients.
   Oral Oncol. 2026;182:108126.
   PubMed     Abstract available
   
   
   August 2026
3. FILIPPINI DM, Carosi F, Tomaciello M, Monte A, et al
   HPV circulating tumor DNA as a potential prognostic and predictive biomarker in head and neck squamous cell carcinoma: a systematic review.
   Oral Oncol. 2026;181:108116.
   PubMed     Abstract available
   
   
   
4. DIETZE A, Zabini A, Schanne DH, Elicin O, et al
   De-escalation of radiotherapy in HPV-negative non-nasopharyngeal head and neck squamous cell carcinoma: a systematic review.
   Oral Oncol. 2026;181:108095.
   PubMed     Abstract available
   
   
   
5. BASKARAN S, Myllerup Jensen J, Kronberg Jakobsen K, Gronhoj C, et al
   Distinguishing lung metastasis from second primary cancer in patients with HPV + oropharyngeal squamous cell carcinoma: A systematic review.
   Oral Oncol. 2026;181:108093.
   PubMed    
   
   
   July 2026
6. GIUDICI F, Polesel J, Tagliabue M, Fratta E, et al
   Evolution of hazard of recurrence and death after surgery for oropharyngeal cancer according to HPV status.
   Oral Oncol. 2026;181:108079.
   PubMed     Abstract available
   
   
   
7. GARCIA-AGULLO J, Santos V, Garcia-Mayea Y, de Luxan-Delgado B, et al
   NGFR expression predicts tumor recurrence in radiotherapy/chemoradiotherapy-treated HPV-negative pharyngeal squamous cell carcinoma.
   Oral Oncol. 2026;180:108080.
   PubMed     Abstract available
   
   
   
8. YAMIN T, Bergman D, Bartal K, Tiomkin E, et al
   The gender gap in HPV Literacy: A Cross-Sectional study of patient awareness of HPV-Related oropharyngeal carcinoma in men in the vaccine era.
   Oral Oncol. 2026;180:108075.
   PubMed     Abstract available
   
   
   June 2026
9. TAPESCU I, Brody RM, Cao AC, Le K, et al
   Predictors and outcomes of pathologic retropharyngeal lymph nodes in HPV-related oropharyngeal cancer.
   Oral Oncol. 2026;180:108056.
   PubMed     Abstract available
   
   
   
10. LOVETT JT, Wotman MT, Westra WH, Ahn S, et al
    Corrigendum to "Long-Term outcomes of induction chemotherapy-guided reduced-dose chemoradiotherapy in poor-risk HPV-Positive oropharyngeal Cancer: Results from the sequential quarterback trials" [Oral Oncol. 174 (2026) 107858].
    Oral Oncol. 2026 Jun 17:108053. doi: 10.1016/j.oraloncology.2026.108053.
    PubMed    
    
    
    
11. UMAR S
    Discordant pN2 Staging in HPV-Associated Oropharyngeal Cancer: CAP/AJCC 9 vs. NCCN/AJCC 8 - Time for Alignment.
    Oral Oncol. 2026;179:108012.
    PubMed    
    
    
    
12. NIJJAR YS, Sapir E, Corn BW, Gensheimer MF, et al
    Evaluation of the ESMO-magnitude of clinical benefit scale version 2.0 for the definitive treatment of HPV positive oropharynx cancer with radiation therapy.
    Oral Oncol. 2026;179:108035.
    PubMed     Abstract available
    
    
    May 2026
13. COSTANTINO A, Paleri V, Williamson A, Zhu J, et al
    Optimizing adjuvant therapy selection with machine learning after transoral surgery in HPV-related oropharyngeal cancer.
    Oral Oncol. 2026;179:108024.
    PubMed     Abstract available
    
    
    
14. SCHAFER A, Zulch L, Steinsdorfer L, Donaubauer AJ, et al
    ATR inhibition in combination with hypofractionated radiotherapy is superior to ATM inhibition with regard to ex vivo CD8 + T cell activation particularly for HPV-negative head and neck cancer cells.
    Oral Oncol. 2026;179:108019.
    PubMed     Abstract available
    
    
    
15. ROOF SA, Sicard RM, Chennareddy S, Ahn S, et al
    Post-treatment circulating tumor DNA clinical features, prognosis in HPV-positive oropharynx cancer.
    Oral Oncol. 2026;178:108003.
    PubMed     Abstract available
    
    
    
16. YILDIZ I, Tasci ES, Yucel S
    HPV-positive oropharyngeal squamous cell carcinoma: risk-adapted treatment strategies and biomarker-guided individualization.
    Oral Oncol. 2026;178:108005.
    PubMed     Abstract available
    
    
    April 2026
17. BAKHTIAR M, Al-Inaya Y, Das D, Margalit DN, et al
    Clearance of circulating HPV DNA during chemoradiation using a next-generation sequencing liquid biopsy.
    Oral Oncol. 2026;178:107984.
    PubMed     Abstract available
    
    
    
18. FAN Z, Sun P, Li L
    Comment on "Blinded comparative evaluation of GPT-generated, online search-derived, and guideline-based answers for HPV-associated oropharyngeal cancer".
    Oral Oncol. 2026;177:107976.
    PubMed    
    
    
    March 2026
19. CARVALHO WA, Carvalho AA, Silveira AA
    Transoral robotic surgery versus definitive (Chemo)radiotherapy in early HPV-positive oropharyngeal cancer: A systematic review and meta-analysis of oncologic outcomes.
    Oral Oncol. 2026;176:107930.
    PubMed     Abstract available
    
    
    February 2026
20. COSTANTINO A, Bossi P, Uccella S, Spriano G, et al
    Beyond binary ENE in HPV-related oropharyngeal cancer: Toward standardized reporting and risk stratification.
    Oral Oncol. 2026 Feb 27:107909. doi: 10.1016/j.oraloncology.2026.107909.
    PubMed    
    
    
    
21. SHU S
    De-escalation in high-risk HPV-positive OPC: critical appraisal of methodology and inference.
    Oral Oncol. 2026;174:107880.
    PubMed    
    
    
    
22. ARDILA CM, Vivares-Builes AM, Pineda-Velez E
    Frozen section analysis in HPV-associated squamous cell carcinoma of unknown primary: Clinical and pathological considerations.
    Oral Oncol. 2026;174:107878.
    PubMed    
    
    
    January 2026
23. LOVETT JT, Wotman MT, Westra WH, Ahn S, et al
    Long-Term outcomes of induction chemotherapy-guided reduced-dose chemoradiotherapy in poor-risk HPV-Positive oropharyngeal Cancer: Results from the sequential quarterback trials.
    Oral Oncol. 2026;174:107858.
    PubMed     Abstract available
    
    
    
24. SRIDHAR S, Moroco A, Gowrishankar S, Mehrad M, et al
    Accuracy of frozen section for HPV-Associated squamous cell carcinoma of unknown primary.
    Oral Oncol. 2026;174:107861.
    PubMed     Abstract available
    
    
    December 2025
25. YUAN S, Gao J
    Methodological considerations in profiling the immune microenvironment and HPV status of oral multiple primary cancers.
    Oral Oncol. 2025;172:107822.
    PubMed    
    
    
    
26. HACK S, Attal R, Geva K, Farzad A, et al
    Blinded comparative evaluation of GPT-generated, online search-derived, and guideline-based answers for HPV-associated oropharyngeal cancer.
    Oral Oncol. 2025;172:107813.
    PubMed     Abstract available
    
    
    
27. WU J, Zhang J, Lin J, Huo Y, et al
    Refining surveillance in surgically treated HPV(+)OPSCC: The path to Risk-Adapted strategies.
    Oral Oncol. 2025;172:107812.
    PubMed    
    
    
    
28. NYIRJESY SC, Al-Inaya Y, Zhang S, Karadaghy OA, et al
    Incidence of HPV-independent second primary malignancies following treatment of HPV-associated malignancy.
    Oral Oncol. 2025;172:107790.
    PubMed     Abstract available
    
    
    
29. CHONG CY, Young RJ, Lim AM, Pizzolla A, et al
    Evaluating CD103(+) intratumoral immune cell abundance and PD-L1 CPS in primary tumors versus lymph nodes in Human papillomavirus associated oropharyngeal Cancer.
    Oral Oncol. 2025;171:107792.
    PubMed     Abstract available
    
    
    
30. HIDALGO CM, Hernandez-Herrera GA, Day CN, Olawuni F, et al
    Access to surgery and high-quality radiotherapy for human papillomavirus related oropharynx cancer.
    Oral Oncol. 2025;171:107768.
    PubMed     Abstract available
    
    
    November 2025
31. TANG Y, Gan H, Gan X
    The diagnostic trade-off in post-treatment surveillance for HPV-positive oropharyngeal carcinoma.
    Oral Oncol. 2025;172:107798.
    PubMed    
    
    
    
32. LI Y, Kou Q, Zheng C, Nov P, et al
    Hpv-driven rewiring of the tumor immune microenvironment through single-cell profiling informs prognosis and therapy in HNSCC.
    Oral Oncol. 2025;172:107789.
    PubMed     Abstract available
    
    
    
33. ZHU AQ, Cassianni CE, Haller T, O'Byrne TJ, et al
    Sensitivity of post-treatment surveillance in detecting recurrence and metastasis in surgically treated HPV-positive oropharyngeal squamous cell carcinoma patients.
    Oral Oncol. 2025;171:107767.
    PubMed     Abstract available
    
    
    October 2025
34. DAS R, Misra SR, Mohapatra SSG
    Refining prognosis and Personalizing Therapy: A Step Forward with Machine learning in HPV-Associated head and neck cancer.
    Oral Oncol. 2025;170:107752.
    PubMed    
    
    
    
35. CAO S, Li Q
    Comments on "Incidence and outcomes of radiation-associated second primary malignancies in HPV-positive oropharyngeal cancer: Long-term follow-up of the quarterback de-escalation trials".
    Oral Oncol. 2025;170:107753.
    PubMed    
    
    
    
36. FENG Z
    Insights on the pilot randomized controlled trial of LEF-SM program for HNC survivors: addressing HPV stratification, adherence measurement, and IMB component dissection.
    Oral Oncol. 2025;170:107748.
    PubMed    
    
    
    
37. MARUDHUPANDI T
    Predictive value of circulating tumor tissue-modified HPV DNA kinetics in induction therapy for oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2025;170:107746.
    PubMed     Abstract available
    
    
    
38. LI S, Garb BF, Qin T, Soppe SE, et al
    Tumor subtype classification tool for HPV-associated head and neck cancers.
    Oral Oncol. 2025;170:107726.
    PubMed     Abstract available
    
    
    
39. NASSIF SJ, Longstreth E, Weinstein GS, Kandula S, et al
    Staged transoral surgery in synchronous HPV-related oropharyngeal cancer.
    Oral Oncol. 2025;170:107738.
    PubMed    
    
    
    
40. KUMARAGURU S, Pandiyan R
    Letter to the Editor: Clinical significance of HPV16 in oropharyngeal cancer: a commentary on recent evidence.
    Oral Oncol. 2025;169:107550.
    PubMed     Abstract available
    
    
    September 2025
41. MISRA SR, Das R
    Beyond MC1675: The imperative for circulating tumour HPV DNA in personalising adjuvant therapy for oropharyngeal Cancer.
    Oral Oncol. 2025;170:107736.
    PubMed    
    
    
    
42. CAVALIERI S, Brakenhoff RH, Leemans CR, Hoebers F, et al
    Transcriptomic based prognostic model versus TNM 9th edition in HPV-positive oropharyngeal cancer.
    Oral Oncol. 2025;170:107685.
    PubMed    
    
    
    
43. ZHOU X, Zhang J, Lou Y, Li W, et al
    Immune and HPV landscape in oral multiple primary cancers compared to single primary cancer.
    Oral Oncol. 2025;169:107646.
    PubMed     Abstract available
    
    
    
44. KANIMOZHI K
    Commentary on "Predictive value of circulating tumor tissue-modified HPV DNA kinetics in induction therapy for oropharyngeal squamous cell carcinoma".
    Oral Oncol. 2025 Sep 11:107678. doi: 10.1016/j.oraloncology.2025.107678.
    PubMed    
    
    
    
45. LUO L, Lu C, Feng H
    Refining SCCUP management: towards safe de-escalation in HPV-positive head and neck cancer-letter on Barrett et al.
    Oral Oncol. 2025;169:107681.
    PubMed    
    
    
    
46. DUAN Y
    Letter to the Editor: Predictive value of circulating tumor tissue-modified HPV DNA kinetics in induction therapy for oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2025;169:107682.
    PubMed    
    
    
    
47. LOVETT JT, Westra WH, Roof S, Bakst RL, et al
    Incidence and outcomes of radiation-associated second primary malignancies in HPV-positive oropharyngeal cancer: long-term follow-up of the quarterback de-escalation trials.
    Oral Oncol. 2025;169:107654.
    PubMed     Abstract available
    
    
    
48. XU S, Lv Y, He H, Han C, et al
    Immune stratification in HPV-negative HNSCC: prognostic significance and prediction of immunotherapy response.
    Oral Oncol. 2025;168:107605.
    PubMed     Abstract available
    
    
    August 2025
49. BARRETT TF, Apicelli AJ, Ramadan S, Pipkorn P, et al
    Management of HPV+ head and neck squamous cell carcinoma with unknown primary in the era of treatment de-escalation.
    Oral Oncol. 2025;169:107631.
    PubMed     Abstract available
    
    
    
50. DUAN Y
    Letter to the editor: Using crowdsourcing to assess HPV knowledge, behaviors, and attitudes in the United States.
    Oral Oncol. 2025;169:107638.
    PubMed    
    
    
    
51. TANG M, Dougherty M, Worona L, Ramos E, et al
    Predictive value of circulating tumor tissue-modified HPV DNA kinetics in induction therapy for oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2025;169:107608.
    PubMed     Abstract available
    
    
    
52. SHARFUNNISA SH
    Letter to the Editor: "Refining nutritional support in HPV + oropharyngeal cancer: Insights from a predictive modelling approach".
    Oral Oncol. 2025;168:107574.
    PubMed    
    
    
    
53. MA C, Zeng H
    Comment on: "Using crowdsourcing to assess HPV knowledge, behaviors, and attitudes in the United States".
    Oral Oncol. 2025;168:107578.
    PubMed     Abstract available
    
    
    July 2025
54. HIEROMNIMON HM, Trzcinska A, Wen FT, Howard FM, et al
    Corrigendum to "Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas". [Oral Oncol. 163 (2025) 107207].
    Oral Oncol. 2025 Jul 27:107510. doi: 10.1016/j.oraloncology.2025.107510.
    PubMed    
    
    
    
55. NARENKUMAR J, Parthipan P
    Letter to the Editor: Impact of the COVID-19 pandemic on diagnosis and disease stage in HPV-positive oropharyngeal cancer: insights and future directions.
    Oral Oncol. 2025;168:107541.
    PubMed     Abstract available
    
    
    
56. KRISHNAN M, Babu S, Rahmathullah A
    Letter to the editor: Toward personalized immunotherapy in OPSCC: Lessons from HPV-driven checkpoint expression.
    Oral Oncol. 2025;168:107547.
    PubMed    
    
    
    
57. SMITH JB, Heiland L, Arnold LD, Simpson MC, et al
    Using crowdsourcing to assess HPV knowledge, behaviors, and attitudes in the United States.
    Oral Oncol. 2025;168:107540.
    PubMed     Abstract available
    
    
    
58. BABU S, Solomon A, Krishnan M
    Revolutionizing HPV-driven cancer surveillance: A commentary on the validation of the HPV-SEQ liquid biopsy platform.
    Oral Oncol. 2025;168:107527.
    PubMed    
    
    
    
59. ABILAJI S, Parthipan P
    Letter to the Editor: Evaluating the risk-modifying effects of HSV-1 and HSV-2 on head and neck cancer in relation to tobacco, alcohol, and HPV-16.
    Oral Oncol. 2025;168:107516.
    PubMed     Abstract available
    
    
    
60. CHAWLA JPS, Madan GK
    Comment on "Current status of circulating tumour DNA and circulating cell alterations in HPV-associated head and neck cancer".
    Oral Oncol. 2025;168:107526.
    PubMed    
    
    
    
61. SINDYA J, Perumal E
    Commentary on "Analytical and clinical performance validation of HPV-SEQ, a novel NGS-based liquid biopsy platform for detection and quantification of human papilloma virus circulating tumor DNA".
    Oral Oncol. 2025;168:107494.
    PubMed    
    
    
    
62. SINGARAVEL V
    Prevalence and genotypic patterns of oral HPV infection in Taiwan-A commentary on the PILLOT study and its relevance to Asian public health strategies.
    Oral Oncol. 2025;167:107479.
    PubMed     Abstract available
    
    
    
63. RAJATHIRAJAN SD
    Commentary on, "Analytical and clinical performance validation of HPV-SEQ, a novel NGS-based liquid biopsy platform for detection and quantification of human papilloma virus circulating tumor DNA".
    Oral Oncol. 2025;167:107484.
    PubMed    
    
    
    June 2025
64. ABILAJI S, Narenkumar J
    Letter to the Editor: Enhancing early detection of HPV associated oropharyngeal cancer: a comparative study of NGS, ddPCR, and qPCR.
    Oral Oncol. 2025 Jun 27:107461. doi: 10.1016/j.oraloncology.2025.107461.
    PubMed     Abstract available
    
    
    
65. EICKELSCHULTE S, Starus A, Murray DH, Keyser KA, et al
    Analytical and clinical performance validation of HPV-SEQ, a novel NGS-based liquid biopsy platform for detection and quantification of human papilloma virus circulating tumor DNA.
    Oral Oncol. 2025;167:107445.
    PubMed     Abstract available
    
    
    
66. ABILAJI S, Narenkumar J
    Letter to the Editor: Human papilloma virus (HPV) associated oral epithelial dysplasia: Emerging evidence, diagnostic challenges, and future directions.
    Oral Oncol. 2025 Jun 23:107434. doi: 10.1016/j.oraloncology.2025.107434.
    PubMed     Abstract available
    
    
    
67. SINGH CHAWLA JP
    Comment on "Circulating miRNAs as diagnostic biomarkers in HPV-associated oropharyngeal squamous cell carcinoma (OPSCC)".
    Oral Oncol. 2025;167:107432.
    PubMed    
    
    
    
68. ARAUJO M, Bouassaly J, Farshadi F, Hier M, et al
    Current status of circulating tumor DNA and circulating cell alterations in HPV-associated head and neck cancer.
    Oral Oncol. 2025;167:107417.
    PubMed     Abstract available
    
    
    
69. LIU N, Kuang Y, Kuang R
    Comment on the epidemiological trends and survival of HPV-related oropharyngeal cancer other than tonsils and base of tongue - a systematic review and meta-analysis.
    Oral Oncol. 2025;167:107371.
    PubMed    
    
    
    
70. KUMARI S, Mishra S, Ali W, Singh US, et al
    Implication of circulating miRNAs as potential diagnostic biomarker in oropharyngeal squamous cell Carcinoma: Association with Human Papilloma Virus.
    Oral Oncol. 2025;165:107305.
    PubMed     Abstract available
    
    
    May 2025
71. RAJATHIRAJAN SD
    Commentary on, "Identification of clinical and pathologic features associated with extranodal extension in patients with HPV-mediated oropharyngeal squamous cell carcinoma".
    Oral Oncol. 2025;166:107394.
    PubMed    
    
    
    
72. OLSON B, Bogan A, Abdel-Halim CN, Rolle-McFarland D, et al
    Identification of clinical and pathologic features associated with extranodal extension in patients with HPV-mediated oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2025;166:107308.
    PubMed     Abstract available
    
    
    
73. YOU J
    Letter to "Adjuvant treatment in elderly patients undergoing transoral surgery for HPV-related oropharyngeal cancer".
    Oral Oncol. 2025;166:107345.
    PubMed    
    
    
    
74. COSTANTINO A, Haughey BH, Alamoudi U, Magnuson JS, et al
    Prognostic significance of distant metastasis site at diagnosis in HPV-related oropharyngeal cancer.
    Oral Oncol. 2025;165:107361.
    PubMed     Abstract available
    
    
    
75. CHENNAREDDY S, Chen S, Levinson C, Genden EM, et al
    Circulating tumor DNA in human papillomavirus-associated oropharyngeal cancer management: A systematic review.
    Oral Oncol. 2025;164:107262.
    PubMed     Abstract available
    
    
    
76. BEDDOK A, Popovtzer A, Calugaru V, Fontaine M, et al
    Proton therapy for primary and recurrent HPV-related oropharyngeal cancer.
    Oral Oncol. 2025;165:107309.
    PubMed     Abstract available
    
    
    April 2025
77. CITRO S, Ghiani L, Doni M, Miccolo C, et al
    HPV-mediated PARP1 regulation and drug sensitization in head and neck cancer.
    Oral Oncol. 2025;165:107307.
    PubMed     Abstract available
    
    
    
78. AL FADEL AM, Jakobsen KK, Jensen LH, Carlander AF, et al
    The epidemiological trends and survival of HPV-related oropharyngeal cancer other than tonsils and base of tongue - a systematic review and meta-analysis.
    Oral Oncol. 2025;165:107311.
    PubMed     Abstract available
    
    
    
79. COSTANTINO A, Sampieri C, Haughey BH, Alamoudi U, et al
    Adjuvant treatment in elderly patients undergoing transoral surgery for HPV-related oropharyngeal cancer.
    Oral Oncol. 2025;165:107312.
    PubMed     Abstract available
    
    
    
80. ROSING F, Plath M, Proctor T, Hofler D, et al
    Post-treatment monitoring of surgically treated oropharyngeal squamous cell carcinoma patients using human papillomavirus cell-free DNA.
    Oral Oncol. 2025;163:107225.
    PubMed     Abstract available
    
    
    March 2025
81. ARDILA CM, Yadalam PK
    AI-driven histopathologic insights in HPV-positive head and neck squamous cell carcinomas.
    Oral Oncol. 2025;163:107261.
    PubMed    
    
    
    
82. DSOUZA G, Tewari S, Troy T, Bleyer P, et al
    Oral HPV incidence and risk factors for acquisition.
    Oral Oncol. 2025;163:107249.
    PubMed     Abstract available
    
    
    
83. LORENZ FJ, Kharouta M, Mahase SS, Goyal N, et al
    Hospital-Based Registry Analysis of Staging Efficacy and Proposed Staging Subclassification for Stage I HPV-Associated Oropharyngeal Squamous Cell Carcinoma.
    Oral Oncol. 2025;163:107251.
    PubMed     Abstract available
    
    
    
84. DERMODY SM, Walline H, Bhambhani C, Tewari M, et al
    Addressing knowledge gaps in HPV-related oropharyngeal cancer prevention: A call for action.
    Oral Oncol. 2025;163:107234.
    PubMed    
    
    
    
85. HIEROMNIMON HM, Trzcinska A, Wen FT, Howard FM, et al
    Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas.
    Oral Oncol. 2025;163:107207.
    PubMed     Abstract available
    
    
    
86. THAVARAJ S, Henley-Smith R, Gregson-Williams H, Yogarajah S, et al
    Clinico-pathological characterisation of human papillomavirus-associated oral epithelial dysplasia.
    Oral Oncol. 2025;162:107182.
    PubMed     Abstract available
    
    
    February 2025
87. KHAN A, Pillay M, Bipath R, Msimang M, et al
    Evolution of testing for the diagnosis of human papillomavirus (HPV) status in head and neck squamous cell carcinoma: Where from and where to?
    Oral Oncol. 2025;162:107208.
    PubMed     Abstract available
    
    
    
88. SUCHAN M, Wuerdemann N, Wagner S, Langer C, et al
    Histological and genetic criteria define a clinically relevant subgroup of HPV-positive oropharyngeal carcinoma.
    Oral Oncol. 2025;162:107209.
    PubMed     Abstract available
    
    
    January 2025
89. XU S, Qin F, Hu W
    Comment on, "Development of a prediction model for tube feeding dependence in HPV-associated oropharyngeal cancer patients undergoing chemoradiotherapy".
    Oral Oncol. 2025;161:107186.
    PubMed    
    
    
    
90. HUTTINGER ZM, Gogineni E, Baliga S, Blakaj DM, et al
    Circulating tumor DNA determines induction chemotherapy response in HPV associated oropharyngeal squamous cell carcinoma: A pilot study.
    Oral Oncol. 2025;161:107179.
    PubMed     Abstract available
    
    
    
91. GIUNCO S, Del Mistro A, Morello M, Lidonnici J, et al
    From infection to immortality: The role of HPV and telomerase in head and neck cancer.
    Oral Oncol. 2025;161:107169.
    PubMed     Abstract available
    
    
    December 2024
92. KAOREY N, Dickinson K, Agnihotram VR, Zeitouni A, et al
    The role of ctDNA from liquid biopsy in predicting survival outcomes in HPV-negative head and neck cancer: A meta-analysis.
    Oral Oncol. 2024;161:107148.
    PubMed     Abstract available
    
    
    
93. DIETRICH N, Watson E, Tadic T, Martino R, et al
    Development of a prediction model for tube feeding dependence in HPV-associated oropharyngeal cancer patients undergoing chemoradiotherapy.
    Oral Oncol. 2024;161:107132.
    PubMed     Abstract available
    
    
    November 2024
94. JEYARAJ G
    Letter to the editor, "Loss of MACROD2 drives radioresistance but not cisplatin resistance in HPV-positive head and neck cancer.".
    Oral Oncol. 2024;160:107092.
    PubMed    
    
    
    
95. VON WITZLEBEN A, Grages A, Thomas J, Ezic J, et al
    Immune checkpoint expression on tumor-infiltrating lymphocytes (TIL) is dependent on HPV status in oropharyngeal carcinoma (OPSCC) - A single-cell RNA sequencing analysis.
    Oral Oncol. 2024;159:107107.
    PubMed     Abstract available
    
    
    
96. MORGENTHALER J, Trommer M, Khor R, Wada M, et al
    Can we safely de-escalate HPV(+) oropharyngeal cancers? - A review of current practices and novel approaches.
    Oral Oncol. 2024;159:107089.
    PubMed     Abstract available
    
    
    October 2024
97. VILLARME A, Ebran N, Pace-Loscos T, Schiappa R, et al
    Prognostic impact of intra tumoral HPV-16 viral load in oropharyngeal squamous cell carcinomas.
    Oral Oncol. 2024;159:107082.
    PubMed     Abstract available
    
    
    
98. GARSET-ZAMANI M, Lomholt AF, Charabi BW, Norling R, et al
    Surgeon-performed intraoperative transoral ultrasound improves the detection of human papillomavirus-positive head and neck cancers of unknown primary.
    Oral Oncol. 2024;159:107073.
    PubMed     Abstract available
    
    
    
99. ZHAO BY, Hirayama S, Goss D, Zhao Y, et al
    Human papillomavirus-associated nasopharyngeal carcinoma: A systematic review and meta-analysis.
    Oral Oncol. 2024;159:107057.
    PubMed     Abstract available
    
    
    
100. DAWSON A, Karimi AH, Shaikh MH, Gazala W, et al
     Loss of MACROD2 drives radioresistance but not cisplatin resistance in HPV-positive head and neck cancer.
     Oral Oncol. 2024;159:107061.
     PubMed     Abstract available
     
     
     September 2024
101. LYU W, Gong J, Zhu L, Xu T, et al
     MR radiomics unveils neoadjuvant chemo-responsiveness with insights into selective treatment de-intensification in HPV-positive oropharyngeal carcinoma.
     Oral Oncol. 2024;159:107049.
     PubMed     Abstract available
     
     
     
102. SANKAR S
     Letter to Editor regarding "Circulating tumor tissue modified viral (TTMV)-HPV DNA in Recurrent, metastatic HPV-driven oropharyngeal cancer".
     Oral Oncol. 2024;159:107020.
     PubMed    
     
     
     August 2024
103. HANNA GJ, Jabalee J, Lukens JN, Sun L, et al
     Circulating tumor tissue modified viral (TTMV)-HPV DNA in Recurrent, metastatic HPV-driven oropharyngeal cancer.
     Oral Oncol. 2024;158:107002.
     PubMed     Abstract available
     
     
     
104. TAMIOLAKIS P, Shah A, Dawson R, Ramasamy S, et al
     HPV- associated sinonasal squamous cell carcinoma with FGFR3::TACC3 fusion. A rare case report.
     Oral Oncol. 2024;157:106983.
     PubMed     Abstract available
     
     
     July 2024
105. JEYACHANDRAN S
     Comment on, "Characterization of oral microbiota in HPV and non-HPV head and neck squamous cell carcinoma and its association with patient outcomes".
     Oral Oncol. 2024;157:106973.
     PubMed     Abstract available
     
     
     
106. MAHDI AGM
     Knowledge, and attitude of medical students about role of human papilloma virus, and vaccine in head and neck cancer.
     Oral Oncol. 2024;156:106939.
     PubMed     Abstract available
     
     
     
107. DAUNGSUPAWONG H, Wiwanitkit V
     Letter to the Editor on "Utility of TTMV-HPV DNA in resolving indeterminate findings during oropharyngeal cancer surveillance".
     Oral Oncol. 2024;156:106930.
     PubMed    
     
     
     
108. CHEN AM
     Translational risk-adapted approaches to de-escalated radiation for human papillomavirus-positive oropharyngeal cancer: Past, present, and future.
     Oral Oncol. 2024;154:106850.
     PubMed     Abstract available
     
     
     June 2024
109. BASTIEN AJ, Ng J, Cong I, Garcia J, et al
     Patient perceptions underlying ctDNA molecular surveillance for HPV(+) oropharyngeal squamous cell carcinoma.
     Oral Oncol. 2024;156:106894.
     PubMed     Abstract available
     
     
     
110. HARIDEVAMUTHU B
     Genomic instability in HPV-positive oropharyngeal squamous cell carcinoma: The role of integration sites in treatment response.
     Oral Oncol. 2024;155:106895.
     PubMed    
     
     
     
111. ROOF SA, Jabalee J, Rettig EM, Chennareddy S, et al
     Utility of TTMV-HPV DNA in resolving indeterminate findings during oropharyngeal cancer surveillance.
     Oral Oncol. 2024;155:106874.
     PubMed     Abstract available
     
     
     
112. BABU S, Krishnan M
     Human papillomavirus and oropharyngeal cancer in HNSCC: A growing concern.
     Oral Oncol. 2024;153:106824.
     PubMed    
     
     
     May 2024
113. COSTANTINO A, Haughey B, Zhu J, Mekhail T, et al
     Sinonasal squamous cell carcinoma in the United States: Temporal and geographic patterns associated with HPV testing and positivity.
     Oral Oncol. 2024;154:106855.
     PubMed     Abstract available
     
     
     April 2024
114. WATON A, Chambers A, Fox H, O'Hara J, et al
     Human Papilloma Virus-16 associated primary adenocarcinoma of the tonsil: Report of two cases and literature review.
     Oral Oncol. 2024;151:106766.
     PubMed    
     
     
     March 2024
115. ZUPANCIC M, Kostopoulou ON, Holzhauser S, Lukoseviciute M, et al
     Human papillomavirus (HPV) load is higher in HPVDNA/p16 positive than in HPVDNA positive/p16 negative oropharyngeal squamous cell carcinoma but does not differ significantly between various subsites or correlate to survival.
     Oral Oncol. 2024;151:106749.
     PubMed     Abstract available
     
     
     
116. FERRARO T, Pershad AR, Arora S, Lee E, et al
     The utility of ultrasonographic surveillance in management of a presumed branchial cleft cyst later confirmed HPV-associated oropharyngeal cancer.
     Oral Oncol. 2024;151:106743.
     PubMed     Abstract available
     
     
     
117. YOUNG RJ, Angel C, Bressel M, Pizzolla A, et al
     Characterising B cell expression and prognostic significance in human papillomavirus positive oropharyngeal cancer.
     Oral Oncol. 2024;150:106687.
     PubMed     Abstract available
     
     
     February 2024
118. MELACHURI M, Kurukulasuriya C, Rumde P, Patel T, et al
     Treatment package time < 14 weeks improves recurrence free and disease specific survival in HPV positive OPC with high-risk features.
     Oral Oncol. 2024;151:106703.
     PubMed     Abstract available
     
     
     
119. ADEN AA, Olawuni FO, Abdel-Halim CN, Zhu AQ, et al
     Association Between Social Determinants of Health, Distance from Treatment Center, and Treatment Type with Outcomes in Human Papillomavirus Associated Oropharyngeal cancer.
     Oral Oncol. 2024;149:106675.
     PubMed     Abstract available
     
     
     January 2024
120. SHENKER RF, Razavian NB, D'Agostino RB Jr, Mowery YM, et al
     Clinical outcomes of oropharyngeal squamous cell carcinoma stratified by human papillomavirus subtype: A systematic review and meta-analysis.
     Oral Oncol. 2024;148:106644.
     PubMed     Abstract available
     
     
     December 2023
121. SICHERO L, Goncalves MG, Bettoni F, Coser EM, et al
     Detection of serum biomarkers of HPV-16 driven oropharynx and oral cavity cancer in Brazil.
     Oral Oncol. 2023;149:106676.
     PubMed     Abstract available
     
     
     November 2023
122. GAFFNEY J, Ramzan A, Dinizulu T, Maley C, et al
     Association of follow-up imaging frequency with temporal incidence and patterns of distant failure following (chemo) radiotherapy for HPV related oropharyngeal cancer.
     Oral Oncol. 2023;148:106645.
     PubMed     Abstract available
     
     
     
123. BARTEMES KR, Gochanour BR, Routman DM, Ma DJ, et al
     Assessing the capacity of methylated DNA markers of cervical squamous cell carcinoma to discriminate oropharyngeal squamous cell carcinoma in human papillomavirus mediated disease.
     Oral Oncol. 2023;146:106568.
     PubMed     Abstract available
     
     
     October 2023
124. BATOOL S, Sethi RKV, Wang A, Dabekaussen K, et al
     Circulating tumor-tissue modified HPV DNA testing in the clinical evaluation of patients at risk for HPV-positive oropharynx cancer: The IDEA-HPV study.
     Oral Oncol. 2023;147:106584.
     PubMed     Abstract available
     
     
     September 2023
125. SHAIKH MH, Dawson A, Prokopec SD, Barrett JW, et al
     Loss of LRP1B expression drives acquired chemo and radio-resistance in HPV-positive head and neck cancer.
     Oral Oncol. 2023;146:106580.
     PubMed     Abstract available
     
     
     
126. SINGH R, Song S
     Clinical outcomes following observation, post-operative radiation therapy, or post-operative chemoradiation for HPV-associated oropharyngeal squamous cell carcinomas.
     Oral Oncol. 2023;146:106493.
     PubMed     Abstract available
     
     
     
127. SHAH R, Tyagi S, Liu C, Judson B, et al
     Extra imaging beyond NCCN surveillance guidelines is cost effective for HPV- but not HPV+ oropharyngeal cancer.
     Oral Oncol. 2023;146:106564.
     PubMed    
     
     
     August 2023
128. VIEIRA GS, Perin MY, Figueiredo-Maciel T, Risuenho AJG, et al
     Induction chemotherapy response of HPV-related multiphenotypic sinonasal carcinoma: First-ever reported therapeutic outcome and a brief literature review.
     Oral Oncol. 2023;146:106555.
     PubMed     Abstract available
     
     
     
129. BHAMBHANI C, Sandford E, Haring CT, Brummel C, et al
     Development of a high-performance multi-probe droplet digital PCR assay for high-sensitivity detection of human papillomavirus circulating tumor DNA from plasma.
     Oral Oncol. 2023;143:106436.
     PubMed     Abstract available
     
     
     July 2023
130. NEWMAN S, Cowart JH, Omar N, Martin E, et al
     HPV-associated oropharyngeal Adenosquamous carcinoma with early metastatic disease detected by ctDNA.
     Oral Oncol. 2023;145:106526.
     PubMed     Abstract available
     
     
     
131. ZENGA J, Awan M, Hadi Razeghi Kondelaji M, Hansen C, et al
     Photoactivated HPPH-Liposomal therapy for the treatment of HPV-Negative head and neck cancer.
     Oral Oncol. 2023;144:106487.
     PubMed     Abstract available
     
     
     
132. DAHLSTROM KR, Sikora AG, Liu Y, Chang CC, et al
     Characterization of the oral microbiota among middle-aged men with and without human papillomavirus infection.
     Oral Oncol. 2023;142:106401.
     PubMed     Abstract available
     
     
     May 2023
133. RETTIG EM, Waterboer T, Sim E, Faden DL, et al
     Relationship of HPV16 E6 seropositivity with circulating tumor tissue modified HPV16 DNA before head and neck cancer diagnosis.
     Oral Oncol. 2023;141:106417.
     PubMed    
     
     
     April 2023
134. HUE J, Valinciute Z, Thavaraj S, Veschini L, et al
     Multifactorial estimation of clinical outcome in HPV-associated oropharyngeal squamous cell carcinoma via automated image analysis of routine diagnostic H&E slides and neural network modelling.
     Oral Oncol. 2023;141:106399.
     PubMed     Abstract available
     
     
     March 2023
135. ZUO N, Ma L, Liu T, Hu W, et al
     Human papillomavirus associated XPF deficiency increases alternative end joining and cisplatin sensitivity in head and neck squamous cell carcinoma.
     Oral Oncol. 2023;140:106367.
     PubMed     Abstract available
     
     
     
136. LAMBERT T, Tasoulas J, Flores M, Sheth S, et al
     Circulating tumor HPV DNA as an alternative method to determine HPV status in oropharyngeal squamous cell carcinoma.
     Oral Oncol. 2023;140:106361.
     PubMed     Abstract available
     
     
     
137. ZHANG L, Freeman T, Sun S, Bhateja P, et al
     The use of plasma circulating tumor DNA for early detection of oligometastatic disease in HPV positive oropharyngeal squamous cell carcinoma.
     Oral Oncol. 2023;139:106357.
     PubMed    
     
     
     
138. DE SOUSA LG, Lazar Neto F, Dal Lago EA, Sikora A, et al
     Human papillomavirus status and prognosis of oropharyngeal high-grade neuroendocrine carcinoma.
     Oral Oncol. 2023;138:106311.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Sexually Transmitted Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum